Elizabeth White
Chief Operating Officer chez RENOVACOR, INC.
Profil
Elizabeth White is currently the Director at Parent Project Muscular Dystrophy.
She is also the Chief Business Officer & Senior VP-Operations at Renovacor Holdings, Inc. and Renovacor, Inc. Her education includes a doctorate from the University of Rochester and an undergraduate degree from Allegheny College.
Postes actifs de Elizabeth White
| Sociétés | Poste | Début |
|---|---|---|
| RENOVACOR, INC. | Chief Operating Officer | - |
Renovacor Holdings, Inc.
 Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | Chief Operating Officer | 19/07/2021 |
Parent Project Muscular Dystrophy
 Parent Project Muscular Dystrophy Miscellaneous Commercial ServicesCommercial Services Parent Project Muscular Dystrophy focuses on finding a cure for Duchenne muscular dystrophy. The company was founded by Pat Furlong in 1984 and is headquartered in Washington, DC. | Director/Board Member | - |
Formation de Elizabeth White
| Rochester Christian University | Doctorate Degree |
| Allegheny College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Parent Project Muscular Dystrophy
Parent Project Muscular Dystrophy Miscellaneous Commercial ServicesCommercial Services Parent Project Muscular Dystrophy focuses on finding a cure for Duchenne muscular dystrophy. The company was founded by Pat Furlong in 1984 and is headquartered in Washington, DC. | Commercial Services |
Renovacor Holdings, Inc.
Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | Health Technology |
Renovacor, Inc.
 Renovacor, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a clinical stage gene therapy company. It researches and develops AAV-based gene therapies for BAG3 gene mutation-associated diseases. Its therapeutic focus is on cardiovascular diseases. The company was founded by Arthur Michael Feldman on June 7, 2013 and is headquartered in Cambridge, MA. | Health Technology |
